HomeFundingAhammune Biosciences raises $5 million to fund novel vitiligo therapy

Ahammune Biosciences raises $5 million to fund novel vitiligo therapy

Published on

spot_img

The funding will enable the company in conducting Phase II human clinical trials for its potential drug candidate for vitiligo – an autoimmune disease that causes the loss of skin colour. Vitiligo has no cure.

Latest articles

AI-based multilingual chatbot ‘myBuddy’ for mental wellbeing

Manah Wellness has launched myBuddy, an AI-based multilingual chatbot, to assist employees with mental...

Ratan Tata cared about making India better: Tech execs pay tributes

His remarkable leadership, marked by a unique blend of humility and confidence, guided TCS...

TCS continues to hire in Q2, adds 5,726 employees

In the previous quarter Q1, the Tata group subsidiary had reversed the declining headcount...

TCS Q2 Results: Profit rises 5% YoY to Rs 11,909 crore, misses estimates

TCS Q2 Results: Tata Consultancy Services (TCS), India's leading software exporter, reported a 5%...

More like this

AI-based multilingual chatbot ‘myBuddy’ for mental wellbeing

Manah Wellness has launched myBuddy, an AI-based multilingual chatbot, to assist employees with mental...

Ratan Tata cared about making India better: Tech execs pay tributes

His remarkable leadership, marked by a unique blend of humility and confidence, guided TCS...

TCS continues to hire in Q2, adds 5,726 employees

In the previous quarter Q1, the Tata group subsidiary had reversed the declining headcount...